Wong, KK and Alty, JE and Goy, AG and Raghav, S and Reutens, DC and Kempster, PA, A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease, Movement Disorders, 26, (8) pp. 1552-1555. ISSN 0885-3185 (2011) [Refereed Article]
Background: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.
Methods: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.
Results: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).
Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties.
|Item Type:||Refereed Article|
|Keywords:||parkinson's, dyskinesia, randomised control trial|
|Research Division:||Biomedical and Clinical Sciences|
|Research Field:||Central nervous system|
|Objective Group:||Clinical health|
|Objective Field:||Efficacy of medications|
|UTAS Author:||Alty, JE (Associate Professor Jane Alty)|
|Web of Science® Times Cited:||23|
|Deposited By:||Wicking Dementia Research and Education Centre|
Repository Staff Only: item control page